Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Mark R Gilbert, Meihua Wang, Kenneth D Aldape, Roger Stupp, Monika E Hegi, Kurt A Jaeckle, Terri S Armstrong, Jeffrey S Wefel, Minhee Won, Deborah T Blumenthal, Anita Mahajan, Christopher J Schultz, Sara Erridge, Brigitta Baumert, Kristen I Hopkins, Tzahala Tzuk-Shina, Paul D Brown, Arnab Chakravarti, Walter J Curran, Minesh P Mehta

Research output: Contribution to journalArticlepeer-review

Abstract

Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM.
Original languageEnglish
JournalJournal of Clinical Oncology
DOIs
Publication statusPublished - 7 Oct 2013

Fingerprint

Dive into the research topics of 'Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial'. Together they form a unique fingerprint.

Cite this